{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:45:40Z","timestamp":1787323540830,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Fujian Province of China","award":["2021J011387"],"award-info":[{"award-number":["2021J011387"]}]},{"name":"Sanming Science and Technology Project","award":["2024-S-084"],"award-info":[{"award-number":["2024-S-084"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-66003-4","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:05:42Z","timestamp":1786161942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological factors associated with HER2 FISH positivity in HER2 IHC 2 + breast cancer: a multicenter study"],"prefix":"10.1038","volume":"16","author":[{"given":"Wen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-1933","authenticated-orcid":false,"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"3","key":"66003_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"10286","key":"66003_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. Breast cancer. Lancet 397(10286), 1750\u20131769 (2021).","journal-title":"Lancet"},{"issue":"11","key":"66003_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"issue":"31","key":"66003_CR4","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31(31), 3997\u20134013 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"66003_CR5","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 36(20), 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"66003_CR6","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J. Clin. Oncol. 41(22), 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"66003_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer [J]. N Engl. J. Med. 387 (1), 9\u201320 (2022).","journal-title":"N Engl. J. Med."},{"issue":"8","key":"66003_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert, C. et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 22(8), 1151\u20131161 (2021).","journal-title":"Lancet Oncol."},{"issue":"17","key":"66003_CR9","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. HER2-low breast cancer: Pathological and clinical landscape. J. Clin. Oncol. 38(17), 1951\u20131962 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"66003_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.prp.2018.10.035","volume":"215","author":"B Xu","year":"2018","unstructured":"Xu, B. et al. Impact of the 2018 ASCO\/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. Pathol. Res. Pract. 215(2), 251\u2013255 (2018).","journal-title":"Pathol. Res. Pract."},{"issue":"7","key":"66003_CR11","first-page":"896","volume":"6","author":"Y Ji","year":"2014","unstructured":"Ji, Y. et al. Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer [J]. J. Thorac. Dis. 6 (7), 896\u2013904 (2014).","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"66003_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10549-012-2101-x","volume":"134","author":"H Zhang","year":"2012","unstructured":"Zhang, H. et al. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: A study of 528 equivocal cases. Breast Cancer Res. Treat. 134(2), 743\u2013749 (2012).","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"66003_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.5858\/133.4.611","volume":"133","author":"GH Vance","year":"2009","unstructured":"Vance, G. H. et al. Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch. Pathol. Lab. Med. 133(4), 611\u2013612 (2009).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"66003_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/modpathol.2013.103","volume":"27","author":"WM Hanna","year":"2014","unstructured":"Hanna, W. M. et al. HER2 in situ hybridization in breast cancer: Clinical implications of polysomy 17 and genetic heterogeneity. Mod. Pathol. 27(1), 4\u201318 (2014).","journal-title":"Mod. Pathol."},{"issue":"18","key":"66003_CR15","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.1158\/1078-0432.CCR-05-0636","volume":"11","author":"MF Press","year":"2005","unstructured":"Press, M. F. et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials [J]. Clin. Cancer Res. 11 (18), 6598\u20136607 (2005).","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"66003_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti, C. et al. HER2-low breast cancer: A new subtype?. Curr. Treat. Options Oncol. 24(5), 468\u2013478 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"66003_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini, F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7(1), 1 (2021).","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"66003_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","volume":"139","author":"EC Inwald","year":"2013","unstructured":"Inwald, E. C. et al. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res. Treat. 139(2), 539\u2013552 (2013).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66003-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:08:26Z","timestamp":1787321306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-66003-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66003"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-66003-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Sanming First Hospital Affiliated to Fujian Medical University (Approval No. Ming Yi Lun [2025] No. 17), as well as the institutional review boards of the participating hospitals, including Sanming Second Hospital and Sanming Integrated Traditional Chinese and Western Medicine Hospital.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the Ethics Committee of Sanming First Hospital Affiliated to Fujian Medical University and the institutional review boards of the participating hospitals due to the retrospective nature of the study and the use of anonymized clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26352"}}